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Novel antihypertensive peptides released by Kluyveromyces marxianus2 
from bovine lactoferrin (LF) have been identified. K. marxianus LF permeate was 3 
fractionated by semi-preparative high performance liquid chromatography and 35 4 
peptides contained in the angiotensin I converting enzyme (ACE)-inhibitory 5 
fractions were identified by using an ion trap mass spectrometer. Based on 6 
peptide abundance and common structural features, six peptides were 7 
chemically synthesized. Four of them (DPYKLRP, PYKLRP, YKLRP and GILRP) 8 
exerted in vitro inhibitory effects on ACE activity and effectively decreased 9 
systolic blood pressure after oral administration to spontaneously hypertensive 10 
rats (SHRs). Stability against gastrointestinal enzymes suggested that the 11 
sequence LRP could contribute to the in vivo effects of parental peptides. Finally, 12 
there were reductions in circulating ACE activity and angiotensin II level in SHRs 13 
after either DPYKLRP or LRP intake, thus confirming ACE inhibition as in vivo14 
mechanism for their antihypertensive effect. 15 
16 
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In the last decade much work has been done to characterize the 21 
antihypertensive effects of peptides derived from food proteins.1 Angiotensin I-22 
converting enzyme (ACE) inhibition is the main target for those peptides. ACE, 23 
as part of the renin-angiotensin system (RAS), hydrolyzes both the inactive 24 
angiotensin I into vasoconstrictor angiotensin II and the vasodilator bradykinin 25 
into an inactive peptide leading to blood pressure upregulation.2 In vitro inhibitory 26 
effect of food protein derived peptides on ACE activity is well established in 27 
contrast with the limited in vivo evidence available for the mechanism of action 28 
underlying their blood pressure lowering effect. Also bioavailability of ACE-29 
inhibitory peptides has been intensively studied since it is known that bioactive 30 
peptides may undergo physiological transformations that determine their activity 31 
in the organism.3 Most research has been focused on milk derived 32 
antihypertensive peptides, some of which have shown beneficial effects in clinical 33 
assays, as reported in different meta-analyses.434 
The use of the proteolytic system of lactic acid bacteria (LAB) to hydrolyze 35 
milk proteins is a successful strategy to release antihypertensive peptides.5 By 36 
contrast few studies exploit the proteolytic potential of yeasts despite their 37 
contribution to proteolysis in dairy products is well established. In this context, the 38 
lactose-fermenting yeast Kluyveromyces marxianus regularly found in milk and 39 
dairy products has been pointed out as a promise candidate to generate 40 
antihypertensive peptides from the whey proteins -lactalbumin and -41 
lactoglobulin.6 Its potential to produce fermented milk with casein-derived ACE-42 
inhibitory peptides has been also described7 although in vivo antihypertensive 43 
effects were not evaluated in any of these reports. 44 
4 
Bovine lactoferrin (LF), a well-characterized component of milk whey, is 45 
also a good source of antihypertensive peptides. We have shown that enzymatic 46 
LF hydrolyzates lower blood pressure and thus exhibit potential as orally effective 47 
antihypertensive compounds.8,9 Moreover, after long-term intake of a pepsin LF 48 
hydrolyzate, there were reductions of circulating ACE activity, angiotensin II and 49 
aldosterone levels, as well as a compensatory increase of renin activity.10 So far, 50 
only five LF-derived peptides with sequences RRWQWR, WQ11, RPYL, LIWKL 51 
and LNNSRAP8 have shown antihypertensive effects after oral administration to 52 
spontaneously hypertensive rats (SHRs), although based on in silico studies 53 
some other antihypertensive peptides are expected to be still identified and 54 
isolated from LF hydrolyzates.1255 
In a previous work, proteolytic yeast strains of Debaryomyces hansenii, 56 
Kluyveromyces lactis and K. marxianus isolated from cheeses13 were screened 57 
for their ability to grow in media with LF as sole nitrogen source and to produce 58 
LF hydrolyzates containing ACE-inhibitory peptides. K. marxianus Km2 strain 59 
grown on LF produced the most potent hydrolyzate which, when orally 60 
administered to SHRs, exerted antihypertensive effect.1461 
The objective of the present study was to identify the LF-derived peptides 62 
produced by K. marxianus Km2 and characterize their antihypertensive effects. 63 
For this purpose a K. marxianus LF permeate enriched in peptides of molecular 64 
weight lower than 3 kDa (pLFH) was fractionated and the main peptides present 65 
in the ACE-inhibitory fractions identified by using an ion trap mass spectrometer. 66 
Selected peptides were evaluated for their inhibitory effects on ACE activity, their 67 
antihypertensive effects in SHRs and their stability against simulated 68 
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gastrointestinal digestion. Finally the in vivo effect of peptides on SHRs blood 69 
ACE activity as well as angiotensin II and aldosterone levels are discussed. 70 
71 
MATERIALS AND METHODS 72 
Materials. Bovine LF was provided by FrieslandCampina Domo (Zwolle, The 73 
Netherlands). ACE from porcine kidney, captopril, and bicinchoninic acid protein 74 
assay kit were purchased from Sigma (St. Louis, MO). Glucose was obtained 75 
from Panreac (Barcelona, Spain), bacteriological peptone was purchased from 76 
Cultimed (Barcelona, Spain) and yeast extract and agar were acquired from 77 
Pronadisa (Madrid, Spain). ACE substrate o-aminobenzoylglycyl-p-78 
nitrophenylalanylproline was provided by Bachem Feinchemikalien (Bubendorf, 79 
Switzerland). Corolase PP (porcine pancreatic extract) was from AB enzymes 80 
(Darmstadt, Germany). Diazepam and ketamine were purchased from Roche 81 
Farma (Madrid, Spain) and Parke-Davis (Alcobendas, Madrid, Spain), 82 
respectively. ACE colorimetric kit was acquired from Bühlmann Laboratories 83 
(Schönenbuch, Switzerland). AssayMax Angiotensin II ELISA kit was from 84 
AssayPro (Saint Charles, MI) and Coat-A-Count Aldosterone 125I RIA kit was 85 
provided by Siemens Medical Solutions Diagnostics (Los Angeles, CA). 86 
87 
Preparation of K. marxianus Lactoferrin Permeate (pLFH) and Fractionation 88 
by Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). 89 
K. marxianus LF hydrolyzate was prepared as previously described and it was 90 
subjected to ultrafiltration through a VivaFlow 50 3kDa cut-off polyethersulfone 91 
membrane (Vivascience, Sartorius Stedim Biotech, Aubagne, France). Resulting 92 
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permeate (pLFH), enriched in peptides of molecular weight lower than 3 kDa 93 
showed an IC50 value of 50.2 ± 2.7 µg/mL. 1494 
Fractionation of pLFH was carried out by RP-HPLC using a Waters system 95 
(Waters Corporation, Milford, MA) equipped with a 1525 Binary HPLC pump, a 96 
2996 Photodiode Array Detector and a 717 plus Autosampler in combination with 97 
a Fraction Collector III. For this purpose, pLFH was applied to a Prep Nova-Pak®98 
HR C18, 60 Å, 6 µm, 7.8 x 300 mm column (Waters). The column was developed 99 
at a flow rate of 4 mL/min. Elution was performed with a linear gradient of solvent 100 
B (acetonitrile with 0.05% TFA) in solvent A (water with 0.05% TFA) from 0 to 101 
20% B in 70 min. Samples of the whole permeate and the fractions (20 mL) were 102 
freeze-dried and kept at -20ºC until reconstitution with distilled water for 103 
determination of the protein content and in vitro ACE-inhibitory effect, as 104 
explained below. 105 
106 
Peptide Sequencing by Reversed-Phase High-Performance Liquid 107 
Chromatography Tandem Mass Spectrometry (RP-HPLC-MS/MS). RP-108 
HPLC-MS/MS analysis of pLFH fractions was performed as described by 109 
Sánchez-Rivera et al.15 with minor changes. The flow rate was 0.2 mL/min and 110 
the injection volume 50 µL. Peptides were eluted using a linear gradient from 0 111 
to 45% of solvent B (acetonitrile:formic acid; 1,000:0.1, v/v) and 55% of solvent 112 
A (water:formic acid; 1,000:0.1% v/v) in 120 min. Data Analysis (version 4.0; 113 
Bruker Daltoniks) was used to process and transform spectra to representing 114 
mass values. BioTools (version 3.2; Bruker Daltoniks) was used to process the 115 
MSn spectra, to perform peptide sequencing and to calculate theoretical masses. 116 
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 Main peptides identified in the pLFH were ordered at >90% purity from 117 
GenScript Corporation (Piscataway, NJ) wherein they were synthesized by solid 118 
phase methods using N-(9-fluorenyl) methoxycarbonyl (Fmoc) chemistry. 119 
120 
In vitro Assay of ACE-Inhibitory Activity. In vitro ACE-inhibitory activity of 121 
pLFH fractions and synthetic peptides was measured using the fluorescent 122 
method described by Sentandreu and Toldrá16 based on the hydrolysis of the 123 
internally quenched fluorescent substrate o-aminobenzoylglycyl-p-124 
nitrophenylalanylproline by the action of ACE. Protein content of peptide fractions 125 
was estimated by the bicinchoninic acid method (BCA) using bovine serum 126 
albumin as standard.7 Synthetic peptide concentration was based on the dry 127 
weight of the peptides. 128 
The IC50 value was defined as the protein/peptide concentration required 129 
to inhibit 50% of the ACE activity, and the value for each experiment was 130 
estimated by non-linear regression of the experimental data to a four-parameter 131 
logistic curve using the software package SigmaPlot v 10.0 (SPSS Inc., Chicago, 132 
IL). 133 
134 
In vivo Assay of Antihypertensive Effect in SHRs. Experimental procedures 135 
were conducted in accordance with the Spanish legislation on Protection of 136 
Animals used for Experimental and other Scientific Purposes and to the 137 
Directives of the European Community on this subject. The study was approved 138 
by the Ethics Committee for Animal Welfare of La Fe Hospital to be carried out 139 
in its accredited animal research facility. 140 
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Male SHRs weighing 230330 g (Charles River Laboratories, Barcelona, 141 
Spain) were housed in temperature-controlled rooms (23°C) with 12 h light/dark 142 
cycles and consumed tap water and standard diets ad libitum. To minimize the 143 
impact of light cycle and feeding on circadian rhythms of blood pressure,17 the 144 
experiments started always at the same time in the morning (9:00 a.m.) in fasted 145 
rats. Indirect measurement of systolic blood pressure (SBP) was carried out in 146 
eighteen awake restrained rats by the non-invasive tail-cuff method using 147 
computer-assisted Non-Invasive Blood Pressure equipment (LE5001 unit with 148 
LE5160R cuff & transducer, Panlab Harvard Apparatus, Cornellá, Barcelona, 149 
Spain). Peptides (up to 10 mg/kg) were orally administered by gastric intubation 150 
in 650 µL of physiological saline. Before the measurements, rats were kept at 151 
37°C during 15 min to make the pulsations of the tail artery detectable. The SBP 152 
was measured before peptide intake (zero time) and 1, 2, 3, 4 and 24 h after 153 
intake. Physiological saline (650 µL) and captopril (50 mg/kg) served as negative 154 
and positive controls, respectively. Each value of SBP was obtained by averaging 155 
at least three consecutive and successful measurements without disturbance of 156 
the signal. Changes in SBP were calculated as the absolute difference (in mm 157 
Hg) with respect to the basal values of measurements obtained just before 158 
peptide administration. 159 
160 
In vitro Simulated Gastrointestinal Digestion and Analysis of Digests by RP-161 
HPLC. Peptides were subjected to a two-stage simulated gastrointestinal 162 
digestion process as previously described.10 Briefly, pepsin (0.2 mg) was added 163 
to aqueous solutions of peptides (10 mL; 1 mM) adjusted at pH 2.0 using 1 N HCl 164 
and incubated at 37°C. After 90 min, the pH was adjusted to 7.5 adding 10 mL of 165 
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0.4 M sodium phosphate buffer at pH 7.5. Corolase PP, a proteolytic enzyme 166 
preparation that contains trypsin, chymotrypsin, and amino and carboxypeptidase 167 
activities, was added (0.2 mg), and the sample was further incubated at 37°C for 168 
150 min. The reaction was stopped by heating at 80ºC for 10 min in a water bath, 169 
followed by cooling at room temperature. Each sample was stored at -20°C until 170 
further analysis by RP-HPLC. 171 
 Analysis of gastrointestinal digests was performed in the same RP-HPLC 172 
system specified above using a Symmetry C18 column (4.6 × 150 mm, 5 µm, 173 
Waters) kept at 40°C. The column was developed at a flow rate of 1 mL/min. 174 
Peptides were eluted with a linear gradient of solvent B (acetonitrile with 0.1% 175 
TFA) in solvent A (water with 0.1% TFA) from 0 to 40% in 20 min and detected 176 
at 214 nm. Peptides LRP and KLRP were quantified in gastrointestinal digests of 177 
DPYKLRP, PYKLRP and YKLRP in accordance to standard curves in water. 178 
179 
Determination of Blood Components of the Renin-Angiotensin System. 180 
Twenty-two rats were anaesthetized by intraperitoneal injection of 5 mg/kg 181 
diazepam and 100 mg/kg ketamine. Blood samples were collected from the 182 
abdominal aorta to obtain both serum and plasma which were kept frozen at -183 
80ºC until the determination of ACE activity, angiotensin II and aldosterone levels.184 
 Direct quantitative in vitro determination of ACE activity was carried out by 185 
using the Bühlmann ACE colorimetric kit according to the manufacturers 186 
instructions. Briefly, it is a kinetic enzymatic assay in which ACE catalyses the 187 
cleavage of the synthetic substrate (FAPGG) into an amino acid derivative and a 188 
dipeptide. The kinetic of this cleavage reaction is measured by recording the 189 
decrease in absorbance at 340 nm. 190 
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Quantitative in vitro measurement of angiotensin II was carried out by 191 
using the AssayMax Angiotensin II ELISA kit according to the manufacturers 192 
instructions. Briefly, this assay employs a quantitative sandwich enzyme 193 
immunoassay technique in which a polyclonal antibody specific for angiotensin II 194 
is pre-coated onto a microplate. The angiotensin II in standards and samples is 195 
sandwiched by the immobilized antibody and biotinylated polyclonal antibody 196 
specific for angiotensin II, which is recognized by a streptavidin-peroxidase 197 
conjugate. A peroxidase enzyme substrate is added and intensity of developed 198 
color is measured. 199 
 Quantitative in vitro measurement of aldosterone was carried out by using 200 
the Coat-A-Count Aldosterone 125I RIA kit according to the manufacturers 201 
instructions. Briefly, it is a solid-phase radioimmunoassay, based on aldosterone-202 
specific antibody immobilized to the wall of the assay tube. 125I-labelled 203 




Fractionation of K. marxianus pLFH: ACE-Inhibitory Activity of Resulting 208 
Fractions and Identification of Major Peptides. K. marxianus pLFH was 209 
subjected to semi-preparative RP-HPLC and the total chromatogram was divided 210 
into 11 fractions which showed IC50 values ranging from 49 to 288 µg/mL. The 211 
three most active fractions (F6, F7 and F11) with IC50 values of 68, 74 and 49 212 
µg/mL, respectively, were analyzed by HPLC-MS/MS and the major peptide 213 
components were sequenced (35 peptides on total, Table 1). 214 
215 
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ACE-Inhibitory Activity of LF-Derived Peptides. A total of 6 peptides (labeled 216 
in Table 1) from those identified in fractions F6, F7 and F11 were chemically 217 
synthesized. These included four sequences (DGKEDL, ESPQTHY, YKLRP and 218 
DPYKLRP) that being among the most abundant in each fraction also fulfilled the 219 
common structural features described for many ACE-inhibitory peptides derived 220 
from food proteins.18 Since the role of specifically C-terminal P residue in 221 
enhancing inhibition has been highlighted in most effective antihypertensive 222 
sequences derived from milk proteins,1 the peptides PYKLRP and GILRP 223 
identified in the most active fraction (F11) were also included in the study despite 224 
not being abundant. Interestingly the yeast proteolytic system produced the set 225 
of sequences DPYKLRP, PYKLRP and YKLRP differing in the amino acidic 226 
residue at the N-terminal end. With the aim of establishing sequence-inhibitory 227 
potency relationships, the peptides KLRP and LRP were also synthesized. 228 
Only the six peptides having a P residue at the C-terminal end showed 229 
detectable inhibitory activity at 20 µM under our in vitro assay conditions. Further 230 
concentration response curves allowed the determination of IC50 values (Table 231 
2) which varied over a 200-fold range. The higher potency as indicated by lower 232 
IC50 value corresponded to the tripeptide LRP. 233 
234 
Antihypertensive Effect of LF-Derived Peptides. The antihypertensive effect 235 
of the six ACE-inhibitory peptide sequences was characterized in SHRs. Average 236 
SBP, measured by the tail-cuff method in awake SHRs, was 200 ± 1 mm Hg (n = 237 
58). Oral administration of the six LF-derived peptides at 10 mg/kg induced 238 
significant reductions in SBP as shown in Figure 1, together with the lack of effect 239 
of oral saline and the antihypertensive effect of captopril (50 mg/kg). Similar to 240 
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the effect caused by captopril, the antihypertensive effect of sequences 241 
DPYKLRP, GILRP and LRP remained significant up to 24 h post administration. 242 
Antihypertensive effects ranged from -26.8 mm Hg for both DPYKLRP and LRP 243 
till -13.2 mm Hg for KLRP. Reductions in SBP caused by DPYKLRP (-26.8 ± 2.4 244 
mm Hg; 1 h post administration) and LRP (-26.8 ± 1.3 mm Hg; 2 h) were 245 
comparable to that of the captopril control (-27.9 ± 2.1 mm Hg; 1 h) (one-way 246 
ANOVA; P>0.05). 247 
The heptapeptide DPYKLRP and the tripeptide LRP were further studied 248 
for dose-dependent antihypertensive effects. Both peptides induced significant 249 
dose-dependent (3, 7 and 10 mg/kg) reductions in SBP at each time point from 1 250 
h to 24 h after oral administration (Figure 2). 251 
252 
Resistance of LF-Derived Peptides to Gastrointestinal Enzymes. The six 253 
antihypertensive peptides were subjected to a hydrolysis process which 254 
simulates gastrointestinal digestion due to the action of gastric and pancreatic 255 
enzymes. The analysis of digests by RP-HPLC (Figure 3) showed that the longer 256 
sequences, DPYKLRP and PYKLRP, were completely hydrolyzed releasing 257 
several fragments. A partial hydrolysis was observed for the pentapeptide YKLRP 258 
(approximately 60% of the initial concentration of the input peptide). In the 259 
conditions tested, sequences KLRP and GILRP were slightly hydrolyzed 260 
(approximately 6% and 12% decrease from the initial concentrations) whereas 261 
LRP was resistant to gastrointestinal enzymes. Noteworthy, in the 262 
gastrointestinal digests of the hydrolyzed peptides, the sequences LRP and 263 
KLRP were detected among others. LRP at concentrations of 525 µM, 600 µM 264 
and 465 µM were detected in the digests of DPYKLRP, PYKLRP and YKLRP, 265 
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respectively. Also a minor quantity of LRP (3 µM) was detected in the KLRP 266 
digest. In the conditions tested, the sequence LRP was not detected in the GILRP 267 
digest. With respect to KLRP, concentrations of 550 µM and 140 µM were 268 
detected in the digests of DPYKLRP and PYKLRP. Also the sequence KLRP was 269 
detected at a concentration of 17 µM in the YKLRP digest. 270 
271 
Effects of LF-Derived Peptides on Blood Components of the Renin-272 
Angiotensin System. The effects of DPYKLRP and LRP (10 mg/kg) on serum 273 
ACE activity and angiotensin II levels, and on plasma aldosterone levels were 274 
studied in SHRs. Captopril (50 mg/kg) was also included as a positive control. 275 
The average serum ACE activity for all measurements carried out in the 276 
three experimental groups before treatment intake was 111.4 ± 1.8 U/L (n=22). 277 
As shown in Figure 4A, ACE activity was significantly reduced in SHRs treated 278 
with DPYKLRP, LRP and captopril at 1 h and 4 h post administration, and 279 
reverted to initial values after 24 h. At 1 h post administration, when maximum 280 
effects were observed, the reduction in ACE activity induced by DPYKLRP (48.1 281 
± 2.5%) was similar to that caused by captopril (43.4 ± 3.1%), and significantly 282 
higher than the reduction induced by LRP (19.1 ± 2.7%) in SHRs (one way 283 
ANOVA followed by Student-Newman-Keuls test). 284 
SHRs showed an average serum angiotensin II level of 71.2 ± 1.3 pg/mL 285 
(n=22) before treatment intake. Angiotensin II levels in SHRs were significantly 286 
reduced by the three treatments at 1 h post administration (Figure 4B). The effect 287 
of LRP reverted at 4 h post administration whereas the reductions caused by the 288 
heptapeptide and captopril reverted at 24 h. When maximum effects were 289 
observed (1 h), the effects caused by DPYKLRP (27.1 ± 0.6% reduction in 290 
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angiotensin II levels) and captopril (33.2 ± 1.3%) were similar and higher than 291 
that provoked by LRP treatment to SHRs (14.8 ± 1.9%; one way ANOVA followed 292 
by Student-Newman-Keuls test).  293 
By contrast to that observed in serum ACE activity and angiotensin II 294 
levels, plasma aldosterone level of SHRs (244.7 ± 1.9 pg/mL; n=22) was not 295 
significantly affected by any of the treatments (data not shown). 296 
297 
DISCUSSION 298 
Yeast products have been used for many years as ingredients and 299 
additives in food processing, although their potential bioactivity has been less 300 
investigated.19 K. marxianus, considered a GRAS (Generally Recognized As 301 
Safe) microorganism, has been isolated from a great variety of habitats, which 302 
results in a high metabolic diversity. Therefore, different biotechnological 303 
applications of this yeast including production of enzymes, of single cell-protein, 304 
and of aroma compounds as well as production of bioingredients from cheese-305 
whey have been described.20 Moreover the beneficial properties of K. marxianus306 
as a human probiotic have been recently assessed.21307 
In this study, we have identified four novel LF-derived peptides which are 308 
reported as ACE-inhibitory and antihypertensive sequences for the first time. To 309 
the best of our knowledge, DPYKLRP, PYKLRP, YKLRP and GILRP produced 310 
by the proteolytic system of K. marxianus Km2 strain when grown in LF as sole 311 
nitrogen source, are the first peptides with antihypertensive effects after oral 312 
administration to SHRs produced by a food-isolated yeast strain. Novel 313 
sequences identified here could at least in part contribute to the ACE inhibiting 314 
and antihypertensive effects of K. marxianus pLFH.14315 
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The four K. marxianus ACE-inhibitory peptides have a C-terminal P 316 
residue. It has been described that the rigid structure of this amino acid may lock 317 
the carboxyl group into a conformation favorable for interaction with the positively 318 
charged residue at the active site of the enzyme.22 Also the four sequences share 319 
the C-terminal tripeptide LRP. Interestingly LRP, which can be found in three 320 
different regions of LF sequence, was pointed out as the sequence responsible 321 
of the in silico high ACE-inhibitory activity of different peptide sequences in LF, 322 
and in accordance with our results, an IC50 value of 0.27 µM was described for 323 
the tripeptide.12 The sequence LIWKL was the most potent LF-derived peptide 324 
described so far (IC50 = 0.47 ± 0.01 µM).8 Here, LRP was the most potent 325 
sequence with an IC50 value (IC50 = 0.35 ± 0.03 µM) slightly lower than that of 326 
LIWKL. Our results suggest that N-terminal elongations decrease in vitro327 
inhibitory potency, although it might not result in lower antihypertensive effects 328 
(see below). Moreover elongations at the C-terminal end of the tripeptide also 329 
provoked a decrease of inhibitory potency since an IC50 value of 4.14 µM was 330 
described for the sequence LRPVAA.23331 
Our results in SHRs show a complex relationship between the in vitro ACE-332 
inhibitory potency and the in vivo antihypertensive effects after oral administration 333 
suggesting a role for gastrointestinal digestion in the formation and degradation 334 
of antihypertensive peptides. When subjected to hydrolysis with gastrointestinal 335 
enzymes all of the peptides tested in this study were hydrolyzed to different 336 
degrees with the exception of LRP. Remarkably this sequence was found in most 337 
of the digests suggesting that the tripeptide might contribute to the in vivo effects 338 
of parental peptides. Further work will be needed to clarify the physiological 339 
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relevance of LRP as well as of the other digestion fragments that could also 340 
contribute to the blood pressure-lowering effects of parental peptides. 341 
Although the IC50 values of LF-derived peptides were by far higher than 342 
that of ACE-inhibitory drug captopril (0.022 M),24 in the conditions tested, oral 343 
administration of DPYKLRP and LRP resulted in a significant decrease in SBP 344 
(13.4% reduction from baseline) similar to that of captopril (14% reduction). 345 
These results are also in agreement with the previously reported antihypertensive 346 
effect of the LF-derived peptide LIWKL (12.1% reduction).8 It has been reported 347 
that food-derived ACE-inhibitory peptides might possess higher in vivo effects 348 
than expected from in vitro inhibitory potencies due to their higher affinity to target 349 
tissues and their slower elimination.25350 
It has been also postulated that other mechanisms of action apart from 351 
ACE inhibition might underlie in vivo antihypertensive effect of ACE-inhibitory 352 
peptides, including short-term vasoactive mechanisms as well as long term-353 
antioxidant and anti-inflammatory mechanisms.26 In this context the sequence 354 
GILRP isolated here is part of the sequences GILRPY and GILRPYL identified in 355 
a proteinase K LF hydrolyzate which exerted in vivo antihypertensive effect. Both 356 
the hydrolyzate and GILRPY showed significant endothelin converting enzyme 357 
(ECE)-inhibitory effects.9 ECE is a key peptidase in the endothelin system that 358 
cleaves precursor inactive big endothelin-1 to produce active endothelin-1 which 359 
has powerful vasoconstrictor and pressor properties.27 The endothelin system 360 
has an increasingly recognized role in blood pressure regulation, and has also 361 
been targeted for hypertension drug treatment. Moreover, we described a set of 362 
peptides derived from LF which showed inhibitory effects on ACE and ECE 363 
activities.28 Also the ACE-inhibitory peptide lactokinin can modulate endothelin-1 364 
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release by endothelial cells.29 Whether the antihypertensive effect showed by 365 
GILRP in this study might be also due to ECE inhibition deserves further studies. 366 
Dose-dependent antihypertensive effects of DPYKLRP and LRP prompted 367 
us to look for a mechanism of action responsible for the graded in vivo responses 368 
of the LF-derived peptides. Determinations of blood RAS components support 369 
ACE inhibition as an in vivo antihypertensive mechanism in SHRs. In vivo ACE-370 
inhibitory effect can be assessed by measuring tissue membrane-anchored or 371 
soluble, circulating ACE activities, and confirmed by measuring circulating levels 372 
of angiotensin II.30 Our results show that serum ACE activity is reduced in SHRs 373 
after oral administration of both peptides. Moreover, inhibition of ACE was 374 
confirmed in peptide treated SHRs by the reduction in angiotensin II level. We 375 
have previously reported that long term administration to SHRs of an 376 
antihypertensive bovine LF pepsin hydrolyzate enriched in low molecular weight 377 
peptides reduced circulating ACE activity, angiotensin II and aldosterone levels.10378 
By contrast, in the present study, the level of serum aldosterone, the adrenal 379 
endocrine component downstream angiotensin II in the renin-angiotensin axis,2380 
was not affected by single-dose treatments with DPYKLRP and LRP. In vivo ACE 381 
inhibition has been also pointed out as the mechanism underlying the blood 382 
pressure reduction of the tripeptide IQP derived from the blue algae Spirulina 383 
platensis since serum ACE and angiotensin II levels were significantly reduced in 384 
SHRs after one-week treatment.31 Nonetheless, the identification of other in vivo385 
mechanisms beyond ACE inhibition underlying antihypertensive effects of the LF-386 
derived peptides identified in this study should be further investigated.  387 
Our results point out K. marxianus as a feasible GRAS microorganism for 388 
the production of novel LF-derived peptides with ACE-inhibitory and 389 
18 
antihypertensive effects. The LF-derived peptides produced by K. marxianus, 390 
DPYKLRP, PYKLRP, YKLRP and GILRP, effectively decreased arterial blood 391 
pressure in SHRs and could, at least in part be responsible for the 392 
antihypertensive properties previously described for K. marxianus LF 393 
hydrolyzate. Also data reported here suggest ACE inhibition as in vivo394 
mechanism for the antihypertensive effects of the sequences DPYKLRP and LRP 395 
in particular, although other mechanisms cannot be discarded. 396 
397 
ABBREVIATIONS USED 398 
ACE, angiotensin I-converting enzyme; BCA, bicinchoninic acid method; ECE, 399 
endothelin converting enzyme; LF, bovine lactoferrin; GRAS, generally 400 
recognized as safe; LAB, lactic acid bacteria; pLFH, lactoferrin permeate 401 
enriched in peptides of molecular weight lower than 3kDa; RAS, renin-402 
angiotensin system; RP-HPLC, reversed-phase high-performance liquid 403 
chromatography; RP-HPLC-MS/MS, reversed-phase high-performance liquid 404 
chromatography tandem mass spectrometry; SBP, systolic blood pressure; 405 
SHRs, spontaneously hypertensive rats; TFA, trifluoroacetic acid. 406 
407 
ACKNOWLEDGEMENT 408 





(1) Martínez-Maqueda, D.; Miralles, B.; Recio, I.; Hernández-Ledesma, B. 413 
Antihypertensive peptides from food proteins: a review. Food & Function 2012, 414 
3, 350-361. 415 
(2) Carey, R. M.; Siragy, H. M. (2003). Newly recognized components of the 416 
renin-angiotensin system: potential roles in cardiovascular and renal regulation. 417 
Endocrine Rev. 2003, 24, 261-271. 418 
(3) Vermeirssen, V.; van Camp, J.; Verstraete, W. Bioavailability of angiotensin 419 
I converting enzyme inhibitory peptides. Br. J. Nutr. 2004, 92, 357-366. 420 
(4) Turpeinen, A. M.; Järvenpää, S.; Kautiainen, H.; Korpela, R.; Vapaatalo, H. 421 
Antihypertensive effects of bioactive tripeptides-random effects meta-analysis. 422 
Ann. Med. 2013, 45, 51-56. 423 
(5) Hernández-Ledesma, B.; Contreras, M.M.; Recio, I. Antihypertensive 424 
peptides: production, bioavailability and incorporation into foods. Adv. Coll. Int. 425 
Sci. 2011, 165, 23-35. 426 
(6) Hamme, V.; Sannier, F.; Piot, J.-M.; Didelot, S.; Bordenave-Juchereau, S. 427 
Crude goat whey fermentation by Kluyveromyces marxianus and Lactobacillus 428 
rhamnosus: contribution to proteolysis and ACE inhibitory activity. J. Dairy Res. 429 
2009, 76, 152-157. 430 
(7) Chaves-López, C.; Tofalo, R.; Serio, A.; Paparella, A.; Sacchetti, G.; Suzzi, 431 
G. Yeasts from colombian Kumis as a source of peptides with angiotensin-I 432 
converting enzyme (ACE) inhibitory activity in milk. Int. J. Food Microbiol. 2012, 433 
159, 39-46. 434 
(8) Ruiz-Giménez, P.; Salom, J. B.; Marcos, J. F.; Vallés, S., Martínez-Maqueda, 435 
D.; Recio, I.; Torregrosa, G.; Alborch, E.; Manzanares, P. Antihypertensive effect 436 
20 
of a bovine lactoferrin pepsin hydrolysate: identification of novel active peptides. 437 
Food Chem. 2012, 131, 266-273. 438 
(9) Fernández-Musoles, R.; Salom, J. B.; Martínez-Maqueda, D.; López-Díez, 439 
J. J.; Recio, I.; Manzanares, P. Antihypertensive effects of lactoferrin 440 
hydrolysates: inhibition of angiotensin- and endothelin-converting enzymes. Food 441 
Chem. 2013 139, 994-1000. 442 
(10) Fernández-Musoles, R.; Manzanares, P.; Burguete, M. C.; Alborch, E; 443 
Salom J. B. In vivo angiotensin I-converting enzyme inhibition by long-term intake 444 
of antihypertensive lactoferrin hydrolysate in spontaneously hypertensive rats. 445 
Food Res. Int. 2013, 54, 627-632. 446 
(11) Ruiz-Giménez, P.; Ibáñez, A.; Salom, J. B.; Marcos, J. F.; López-Díez, J. 447 
J.; Vallés, S.; Torregrosa, G.; Alborch, E.; Manzanares, P. Antihypertensive 448 
properties of lactoferricin B-derived peptides. J. Agric. Food Chem. 2010, 58,449 
6721-6727. 450 
(12) Vermeirssen, V.; van der Bent, A.; van Camp, J.; van Amerongen, A.; 451 
Verstraete, W. A quantitative in silico analysis calculates the angiotensin I 452 
converting enzyme (ACE) inhibitory activity in pea and whey protein digests. 453 
Biochim. 2004, 86, 231-239. 454 
(13) Padilla, B.; Manzanares, P.; Belloch, C. (2014). Yeast species and genetic 455 
heterogeneity within Debaryomyces hansenii along the ripening process of 456 
traditional ewes' and goats' cheeses. Food Microbiol. 2014, 38, 160-166.457 
(14) García-Tejedor, A.; Padilla, B.; Salom, J. B.; Belloch, C.; Manzanares, P. 458 
Dairy yeasts produce milk protein-derived antihypertensive hydrolysates. Food 459 
Res. Int. 2013, 53, 203-208. 460 
21 
(15) Sánchez-Rivera, L.; Recio, I.; Ramos; M.; Gómez-Ruiz, J. A. Peptide 461 
profiling in cheeses packed using different technologies. J. Dairy Sci. 2013, 96, 462 
3551-3557. 463 
(16) Sentandreu, M. A.; Toldrá, F. A rapid, simple and sensitive fluorescence 464 
method for the assay of angiotensin-I converting enzyme. Food Chem. 2006, 97, 465 
546-554. 466 
(17) van den Buuse, M. Circadian rhythms of blood pressure and heart rate in 467 
conscious rats: effects of light cycle shift and timed feeding. Physiol. Behav. 1999, 468 
68, 9-15. 469 
(18) Murray, B. A.; FitzGerald, R. J. Angiotensin converting enzyme inhibitory 470 
peptides derived from food proteins: biochemistry, bioactivity and production. 471 
Curr. Pharm. Des. 2007, 13, 773-791. 472 
(19) Abbas, C. A. (2006). Production of antioxidants, aromas, colours, flavours 473 
and vitamins by yeasts. In Yeasts in food and beverages; Querol, A., Fleet, G. 474 
H., Eds.; Springer: New York, NY, 2006; pp. 285-334. 475 
(20) Fonseca, G. G.; Heinzle, E.; Wittmann, C.; Gombert, A. K. The yeast 476 
Kluyveromyces marxianus and its biotechnological potential. Appl. Microbiol. 477 
Biotechnol. 2008, 79, 339-354. 478 
(21) Maccaferri, S.; Klinder, A.; Brigidi, P.; Cavina, P.; Costabile, A. Potential 479 
probiotic Kluyveromyces marxianus B0399 modulates the immune response in 480 
Caco-2 cells and peripheral blood mononuclear cells and impacts the human gut 481 
microbiota in an in vitro colonic model system. App. Environ. Microbiol. 2012, 78,482 
956-964. 483 
22 
(22) Cushman, D. W.; Cheung, H. S.; Sabo, E. F.; Ondetti, M. A. Design of 484 
potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl 485 
and mercaptoalkanoyl amino acids. Biochem. 1977, 16, 5484-5491. 486 
(23) Lee, N-Y.; Cheng, J-T.; Enomoto, T.; Nakamura, I. The antihypertensive 487 
activity of angiotensin-converting enzyme inhibitory peptide containing in bovine 488 
lactoferrin. Chin. J. Physiol. 2006, 49, 67-73. 489 
(24) Ondetti, M. A.; Rubin, B.; Cushman, D. W. Design of specific inhibitors of 490 
angiotensin-converting enzyme: new class of orally active antihypertensive 491 
agents. Science 1977, 196, 441-444. 492 
(25) Fujita, H.; Yoshikawa, M. LKPNM: a pro-drug type ACE-inhibitory peptide 493 
derived from fish protein. Immunopharmacol. 1999, 44, 123-127. 494 
(26) Marques, C.; Amorim, M.M.; Pereira, J.O.; Pintado, M.E.; Moura, D.; 495 
Calhau, C.; Pinheiro, H. Bioactive peptides: are there more antihypertensive 496 
mechanisms beyond ACE inhibition? Curr. Pharm. Des. 2012, 18, 4706-4713. 497 
(27) Schiffrin, E. L. Vascular endothelin in hypertension. Vasc. Pharmacol. 2005, 498 
43, 19-29. 499 
(28) Fernández-Musoles, R.; López-Díez, J. J.; Torregrosa, G.; Vallés, S.; 500 
Alborch, E.; Manzanares, P.; Salom J. B. Lactoferricin B-derived peptides with 501 
inhibitory effects on ECE-dependent vasoconstriction. Peptides 2010, 31, 1926-502 
1933. 503 
(29) Maes W.; van Camp J.; Vermeirssen V.; Hemeryck M.; Ketelslegers J. M.; 504 
Schrezenmeir J.; van Oostveldt, P.; Huyghebaert, A. Influence of the lactokinin 505 
Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by 506 
endothelial cells. Reg. Peptides 2004, 118, 105-109. 507 
23 
(30) Coates, D. The angiotensin converting enzyme (ACE). Int. J. Biochem. Cell 508 
Biol. 2003, 35, 769-773. 509 
(31) Lu, J.; Sawano, Y.; Miyakawa, T.; Xue, Y-L.; Cai, M-Y.; Egashira, Y.; Ren, 510 
D-F.; Tanokura, M. One-week antihypertensive effect of Ile-Gln-Pro in 511 
spontaneously hypertensive rats. J. Agric. Food Chem. 2011, 59, 559-563. 512 
513 
FUNDING 514 
This work was supported by grant AGL2010-21009 from ‘Ministerio de Educación 515 
y Ciencia - FEDER’, Consolider Ingenio 2010, Fun-C-Food, CSD2007-00063 and 516 
RETICS INVICTUS RD12/0014/0004 from ‘Instituto de Salud Carlos III’. A. 517 
García-Tejedor is recipient of a predoctoral fellowship from ‘Ministerio de 518 
Educación y Ciencia’ (BES-2011-044424). 519 
520 
24 
Figure captions 521 
Figure 1. Time course of systolic blood pressure (SBP) changes after oral 522 
administration of physiological saline, captopril (50 mg/kg) and LF-derived 523 
peptides (10 mg/kg) to SHRs. Pressure changes (SBP) are expressed in 524 
absolute values (mm Hg) and data are expressed as mean ± SEM from 6-7 525 
determinations. *P<0.01 versus control saline group (one-way ANOVA followed 526 
by Dunnett multiple comparison tests). 527 
Figure 2. Time course of systolic blood pressure (SBP) changes after oral 528 
administration of increasing doses of DPYKLRP (A) and LRP (B) to SHRs. () 529 
physiological saline, () 3 mg/kg, () 7 mg/kg, () 10 mg/kg. Pressure changes 530 
are expressed in absolute values (mm Hg) and data are expressed as mean ± 531 
SEM from 5-8 determinations. Different letters indicate significant differences 532 
among doses at each time point (one-way ANOVA followed by Student-Newman-533 
Keuls multiple comparison tests, P<0.05). 534 
Figure 3. RP-HPLC chromatograms of peptides before (dashed line) and after 535 
(solid line) being submitted to a simulated gastrointestinal digestion. (A) 536 
DPYKLRP, (B) PYKLRP, (C) YKLRP, (D) KLRP, (E) LRP, (F) GILRP. 537 
Figure 4. Time course of changes produced in the levels of blood components of 538 
the renin-angiotensin system after oral administration of DPYKLRP (10 mg/kg), 539 
LRP (10 mg/kg) and captopril (50 mg/kg) to SHRs. (A) Serum angiotensin I-540 
converting enzyme (ACE) activity. (B) Serum angiotensin II levels. Data are mean 541 
± SEM from 4-10 determinations. *P<0.05 versus baseline values at time 0 h, 542 
**P<0.01 versus baseline values at time 0 h (one-way ANOVA followed by 543 
Dunnett multiple comparison tests). 544 
545 
25 
Table 1. Identification of Peptides Contained in the F6, F7 and F11 RP-HPLC 
Fractions of the K. marxianus Lactoferrin Permeate (pLFH) 
aFractions are termed as in Figure 1. 
bCharge of precursor ion: 1 
cCalculated monoisotopic mass 
dChemically synthesized peptides are labelled in bold. 
546 










F6 755.397 754.390 754.372 f(601 – 607) SDRAAHV 
 779.362 778.354 778.361 f(652 – 658) GGRPTYE 
 646.390 645.382 645.333 f(335 – 340) AEEVKA 
 676.329 675.322 675.308 f(261 – 266) DGKEDLd
 624.367 623.360 623.303 f(283 – 287) SRSFQ 
 638.438 637.431 637.355 f(611 – 615) LLHQQ 
 668.412 667.405 667.340 f(602 – 607) DRAAHV 
 607.349 606.341 606.276 f(68 – 72) GRDPY 
 439.113 438.105 438.211 f(319 – 322) YLGS 
 722.407 721.400 721.376 f(276 – 281) EKFGKN 
F7 908.426 907.419 907.404 f(652 – 659) GGRPTYEE 
 575.214 574.206 574.260 f(536 – 541) DVGDVA 
 714.516 713.509 713.480 f(435 – 441) AVAVVKK 
 775.417 774.409 774.376 f(260 – 266) VDGKEDL 
 504.075 503.068 503.223 f(536 – 540) DVGDV 
 851.407 850.400 850.382 f(653 – 659) GRPTYEE 
 548.256 547.249 548.226 f(503 – 508) ALCAGD 
 636.454 635.447 635.375 f(338 – 342) VKARY 
 582.226 581.219 581.270 f(660 – 664) YLGTE 
 572.331 571.324 571.333 f(28 – 33) KLGAPS 
 496.155 495.148 495.244 f(283 – 286) SRSF 
 779.466 778.459 778.434 f(98 – 104) VKKGSNF 
 861.351 860.344 860.366 f(86 – 92) ESPQTHYd
F11 848.427 847.420 847.455 f(68 – 74) GRDPYKL 
 823.472 822.465 822.387 f(224 – 229) RDQYEL 
 693.239 692.232 692.281 f(189 – 194) YFGYSG 
 743.382 742.375 742.386 f(141 – 147) SLEPLQG 
 773.499 772.492 772.460 f(71 – 76) PYKLRPd
 907.415 906.408 906.420 f(563 – 569) NLNREDF 
 780.312 779.305 779.345 f(101 – 107) GSNFQLD 
 677.293 676.286 676.318 f(445 – 450) GLTWNS 
 676.510 675.503 675.407 f(72 – 76) YKLRPd
 555.428 554.421 554.354 f(130 – 134) GILRPd
 888.482 887.475 887.487 f(70 – 76) DPYKLRPd
 414.156 413.149 413.227 f(144 – 147) PLQG 
26 
Table 2. Inhibitory Potency of Selected LF-Derived Peptides on ACE Activity 
peptide IC50 (µM)a
DPYKLRP 30.5 ± 1.4 (c) 
 PYKLRP 10.2 ± 1.2 (b) 
  YKLRP 16.5 ± 0.7 (b) 
   KLRP 91.6 ± 4.0 (d) 
    LRP 0.35 ± 0.03 (a) 
  GILRP 90.7 ± 5.0 (d) 
aInhibitory potency is expressed as IC50 and data are mean  SEM of at least 3 
independent experiments. Data with the same letter are not significantly different, P > 
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